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Abstract 
Background 
Studies of the association between the apolipoprotein C3 gene (APOC3) rs5128 
polymorphism and plasma levels of apolipoprotein C3 (APOC3) and lipids have reported 
apparently conflicting findings. This meta-analysis aimed to investigate the associations of 
the rs5128 polymorphism with fasting APOC3 and lipid levels. 
Methods 
The following information was abstracted for each study: ethnicity, age, sex, health 
condition, sample size, genotyping and lipid assay methods, mean and standard deviation or 
standard error by genotypes for APOC3 and lipid variables. There were 42 eligible studies 
with 23846 subjects included in this meta-analysis. A dominant model was used for this 
meta-analysis. 
Results 
The results showed that the carriers of the variant allele G had higher levels of APOC3 
[standardized mean difference (SMD): 0.22, 95% confidence interval (CI): 0.12-0.31, P < 
0.00001], triglycerides (TG) (SMD: 0.33, 95% CI: 0.23-0.44, P < 0.00001), total cholesterol 
(TC) (SMD: 0.15, 95% CI: 0.09-0.22, P < 0.00001), and low-density lipoprotein cholesterol 
(LDL-C) (SMD: 0.11, 95% CI: 0.04-0.17, P = 0.001) than the non-carriers. No significant 
association between the APOC3 rs5128 polymorphism and lower levels of high-density 
lipoprotein cholesterol (HDL-C) was detected under the dominant model (SMD: −0.03, 95% 
CI: −0.06-0.01, P = 0.156). 
Conclusions 
The results from the present meta-analysis demonstrate a significant association between the 
APOC3 rs5128 polymorphism and higher levels of APOC3, TG, TC and LDL-C, but further 
studies are needed to elucidate the underlying mechanisms. 
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Introduction 
Cardiovascular disease (CVD) is now the leading cause of death worldwide, both in 
developed countries and in many developing countries [1]. After decades of study, a number 
of CVD risk factors have been identified. Among these risk factors, dyslipidemia, 
characterized by elevations of triglycerides (TG), total cholesterol (TC) and/or low-density 
lipoprotein cholesterol (LDL-C), or reduction of high-density lipoprotein cholesterol (HDL-
C) levels, accounts for at least 50% of the population-attributable risk for CVD [2]. In recent 
years, much has been learned about the chromosomal regions and specific genes that 
influence plasma lipid or lipoprotein levels [3]. However, due to various reasons, it is 
difficult to identify the susceptibility genes and most associations have not been replicated 
across studies. 
The apolipoprotein C3 gene (APOC3) is a member of the APOA1/C3/A4/A5 gene cluster and 
located on chromosome 11q23, an area in strong linkage with lipid metabolism [3]. 
Apolipoprotein C3 (APOC3) is an essential constituent of TG-rich particles including 
chylomicron and very low-density lipoprotein (VLDL), to a less extent of high-density 
lipoprotein (HDL). Evidence from gene engineering studies suggested that the main role of 
APOC3 could be involved in the regulation of plasma TG levels [4,5]. Additional copies of 
human APOC3 in transgenic pig were associated with hypertriglyceridemia (HTG) [4], 
whereas APOC3 deficiency prevents hyperlipidemia induced by apolipoprotein E gene 
overexpression [5]. In vitro, APOC3 was found to delay the catabolism of VLDL by 
inhibiting the lipoprotein lipase (LPL) which is the rate-limiting enzyme for TG hydrolysis 
[6]. Furthermore, it also interferes the apolipoprotein E-mediated remnant removal by 
displacement of apolipoprotein E from VLDL particles in vivo [7,8]. APOC3 also play 
important roles in modulating other lipid variables [9]. Given its role in plasma lipid 
metabolism, APOC3 is considered a candidate gene for dyslipidemia. 
Of several variants within APOC3, a transversion from C to G in the 3' untranslated region 
(3'UTR) of exon 4 results in a rs5128 polymorphism (also known as SstI, sacI, 3238C > G or 
3175C > G). A recent meta-analysis [10] demonstrated that the rs5128 polymorphism is 
associated with CVD, but whether this polymorphism is also associated with dyslipidemia 
remains to be further examined. A large body of studies has investigated the associations of 
this polymorphism with plasma APOC3 and lipid levels [11-52]. Some studies found that this 
polymorphism is associated with higher plasma levels of APOC3 [14,20,27,41,42], 
TG[18,20,23,25,28,30,32,33,38,41,42,44,46,51], TC[18,32,51] and LDL-C [30,51], and 
lower levels of HDL-C[24]. However, the results from other studies were conflicting and 
inconclusive. In this paper, a meta-analysis was performed on previous reports to investigate 
the associations of the rs5128 polymorphism with APOC3 and fasting lipid levels. Our 
analysis results can provide the opportunity to elucidate the interrelationship among the 
rs5128 polymorphism, dyslipidemia and CVD. 
Methods 
Identification and eligibility of relevant studies 
All articles published before May 2014 on the associations of the APOC3 rs5128 
polymorphism with plasma APOC3 and lipid levels were identified. The language was 
limited to English. A comprehensive search of the literature was carried out by using PubMed 
and EMBASE. The keywords used for this search were “APOC3 OR APOC-III OR 
apolipoprotein C-III OR apolipoprotein CIII OR apolipoprotein C3 OR APOC3 OR APO 
C3” concatenated with “polymorphism OR variant OR SNP OR mutation”. This meta-
analysis is limited to APOC3 and the plasma lipid variables including TG, TC, LDL-C, and 
HDL-C. The studies that fulfilled the following criteria were included: (1) data reported on 
fasting variables; (2) data reported on APOC3 and/or at least one of the four plasma lipid 
variables; (3) pre-intervention baseline data were used in interventional studies; (4) the 
studies in which mean plasma lipid levels and standard deviations (SD) or standard errors 
(SE) by genotype were available. In order to find other published work which was not 
indexed by PubMed and EMBASE, all references cited in the included articles were 
reviewed. Case reports, review articles, abstracts, animal studies, reports with incomplete 
data, and studies based on pedigree data were excluded. 
Data extraction 
The irrelevant and overlapping studies were excluded after being reviewed independently by 
two reviewers using a structured data collection form. The results were compared, and the 
disagreements were resolved by discussion. Regarding the overlapping articles, only those 
publications that reported the most extensive information were included. For each study 
included in the present meta-analysis, the following information was extracted: first author, 
year of publication, ethnicity, country of origin, age, sex, health condition, genotyping and 
lipid assay methods, sample size, mean APOC3 or lipid variables and SD or SE by 
genotypes. 
Statistical analysis 
All data were presented as mean ± SD in this analysis. For those included articles in which 
mean ± SE was given, the value of the SD was calculated. The STATA software package v 
10.0 (Stata Corporation, College Station, TX) was used for the meta-analysis. Due to the low 
frequencies of the GG genotype, a dominant model [(CG + GG) versus CC] was employed to 
ensure adequate statistical power. When data was presented for more than one subpopulation 
(for example, female or male subjects, the subjects with CVD or type 2 diabetes, the subjects 
from different ethnicity) in one article, each subpopulation was treated as a separate 
comparison in this meta-analysis. In addition, subgroup analyses were conducted by age, 
gender, ethnicity and health condition. Age subgroups were defined as adults and children 
(under 18 years old). Ethnic subgroups were defined as Caucasian, Asian, and the populations 
of other ethnic origins. The meta-analyses on the subgroup were only performed with at least 
four comparisons to ensure adequate statistical power. 
The pooled standardized mean difference (SMD) and its 95% confidence interval (CI) were 
used to assess the differences of the variables between the genotypes. A random effects 
model was used for all analyses because both between-study and within-study heterogeneity 
is considered in this model; it provides a more conservative evaluation of the significance of 
the association than the fixed effects model [53]. Heterogeneity between studies was tested 
by Cochran's χ2-based Q-statistic at a significance level of P < 0.05. Galbraith plot was used 
to detect the potential sources of heterogeneity, and the pooled SMD was recalculated after 
removal of the outlier studies identified in the plot. The populations in the studies were tested 
for Hardy-Weinberg equilibrium (HWE) by χ2 test; the significance level is defined as α < 
0.05. Publication bias was assayed by Egger's linear regression test [54], and a significance 
level of 0.05 was used to indicate the presence of potential publication bias. 
Results 
Characteristics of the included studies 
Initial search of the literature yielded 646 publications. Five hundred and eighteen studies 
were excluded according to title and abstract. Then full text articles were retrieved and 
assessed on the basis of the inclusion criteria. Eighty-six papers were ineligible for the 
following reasons: 57 papers did not provide complete data for this meta-analysis, 24 papers 
presented data on other polymorphisms, 2 papers had subjects overlap with other 
publications, and 3 studies were based on pedigree data. In the end, 42 studies were selected 
for this meta-analysis. 
The characteristics of the 42 included studies were summarized in Table 1. Of these, 14 
studies [11,13,14,19,20,22-24,26,27,30,33,41,42], 40 studies [11-13,15-39,41-52], 31 studies 
[11,13,15,17-19,21-24,26,28-36,38-40,44,45,47-52], 27 studies [17,18,21-24,26,28,30-34,36-
41,44,45,47-52] and 34 studies [11,15-19,21-24,26,28,30-41,43-52] presented the data on 
APOC3, TG, TC, LDL-C and HDL-C, respectively. Twenty-six studies [12,14-18,20-23,25-
30,32,35,39-41,43,44,46-48], 10 studies [11,19,24,33,34,37,38,42,45,49] and 6 studies 
[13,31,36,50-52] involved Caucasians, Asians, and the subjects of other ethnic origins, 
respectively. Seven studies [12,16,21,22,30,35,50] only involved males, and the other 35 
studies involved both males and females, among which 9 studies 
[14,23,26,28,29,36,37,43,47] separately provided data for males and females. Three studies 
[20,36,47] involved children. Four studies [18,33,38,48] and 9 studies [12,15-
17,19,34,35,38,50] involved type 2 diabetes and CVD, respectively. Twenty-three studies 
[12,14-17,19,23,25,26,28,29,34-38,43,45,47-50,52] separately provided data for more than 
one subpopulation, and each subpopulation was treated as a separate comparison. Genotype 
distribution in 6 populations or subpopulations [25,27,31,38,50,51] significantly deviated 
from HWE. The units of APOC3 or plasma lipids used in the eligible studies included mg/dl 
or mmol/L. The complete plasma APOC3 and lipid data by genotype can be found in 
Additional file 1: Table S1. 
Table 1 Characteristics of individual studies included in the meta-analysis 
First author, reference year Ethnicity Gender Study population Outcomes 
Aburatani [11] 1988 Asian M/F Subjects with hyperlipidemia and controls APOC3, TG, TC, HDL-C 
Paulweber1 [12] 1988 Caucasian M Patients with CVD TG 
Paulweber2 [12] 1988 Caucasian M Subjects without CVD TG 
Ahn [13] 1991 Other M/F Random subjects APOC3, TG, TC 
Shoulders1 [14] 1991 Caucasian M Healthy subjects APOC3 
Shoulders2 [14] 1991 Caucasian F Healthy subjects APOC3 
Ordovas1 [15] 1991 Caucasian M/F Patients with CVD TG, TC, HDL-C 
Ordovas2 [15] 1991 Caucasian M/F Healthy population TG, TC, HDL-C 
Tybjaerg-Hansen1 [16] 1993 Caucasian M Subjects with CVD TG, HDL-C 
Tybjaerg-Hansen2 [16] 1993 Caucasian M Subjects without CVD TG, HDL-C 
Miettinen1 [17] 1994 Caucasian M/F Subjects with CVD TG, TC, LDL-C, HDL-C 
Miettinen2 [17] 1994 Caucasian M/F Subjects without CVD TG, TC, LDL-C, HDL-C 
Rigoli [18] 1995 Caucasian M/F Patients with type 2 diabetes TG, TC, LDL-C, HDL-C 
Bai1 [19] 1995 Asian M/F Subjects with CVD APOC3, TG, TC, HDL-C 
Bai2 [19] 1995 Asian M/F Subjects without CVD APOC3, TG, TC, HDL-C 
Shoulders [20] 1996 Caucasian M/F Random healthy children APOC3, TG 
López-Miranda [21] 1997 Caucasian M Random healthy youth TG, TC, LDL-C, HDL-C 
Kee [22] 1999 Caucasian M Random subjects APOC3, TG, TC, LDL-C, HDL-C 
Dallongeville1 [23] 2000 Caucasian M Random subjects APOC3, TG, TC, LDL-C, HDL-C 
Dallongeville2 [23] 2000 Caucasian F Random subjects APOC3, TG, TC, LDL-C, HDL-C 
Wu [24] 2000 Asian M/F Random subjects without CVD APOC3, TG, TC, LDL-C, HDL-C 
Waterworth1 [25] 2000 Caucasian M/F Non-smokers TG 
Waterworth2 [25] 2000 Caucasian M/F Exsmokers (cessation for minimum of 1 year) TG 
Waterworth3 [25] 2000 Caucasian M/F Current smokers TG 
Russo1 [26] 2001 Caucasian M Framingham Offspring Study APOC3, TG, TC, LDL-C, HDL-C 
Russo2 [26] 2001 Caucasian F Framingham Offspring Study APOC3, TG, TC, LDL-C, HDL-C 
Olivieri [27] 2002 Caucasian M/F Subjects with or without CVD APOC3, TG 
Corella1 [28] 2002 Caucasian M Random healthy subjects TG, TC, LDL-C, HDL-C 
Corella2 [28] 2002 Caucasian F Random healthy subjects TG, TC, LDL-C, HDL-C 
Rodrigo1 [29] 2002 Caucasian M Patients undergoing kidney transplantation TG, TC 
Rodrigo2 [29] 2002 Caucasian F Patients undergoing kidney transplantation TG, TC 
Couillard [30] 2003 Caucasian M Abdominally obese subjects APOC3, TG, TC, LDL-C, HDL-C 
Brown [31] 2003 Other M/F Random subjects TG, TC, LDL-C, HDL-C 
Espino-Montoro [32] 2003 Caucasian M/F Hypertensive patients TG, TC, LDL-C, HDL-C 
Chen [33] 2004 Asian M/F Patients with type 2 diabetes APOC3, TG, TC, LDL-C, HDL-C 
Chhabra1 [34] 2004 Asian M/F Patients with CVD TG, TC, LDL-C, HDL-C 
Chhabra2 [34] 2004 Asian M/F Subjects without CVD TG, TC, LDL-C, HDL-C 
Liu1 [35] 2004 Caucasian M Subjects with CVD TG, TC, HDL-C 
Liu2 [35] 2004 Caucasian M Subjects without CVD TG, TC, HDL-C 
de França1 [36] 2005 Other M Healthy children TG, TC, LDL-C, HDL-C 
de França2 [36] 2005 Other F Healthy children TG, TC, LDL-C, HDL-C 
Arai1 [37] 2005 Asian M Random subjects TG, LDL-C, HDL-C 
Arai2 [37] 2005 Asian F Random subjects TG, LDL-C, HDL-C 
Liu1 [38] 2005 Asian M/F Patients with CVD TG, TC, LDL-C, HDL-C 
Liu2 [38] 2005 Asian M/F Patients with type 2 diabetes TG, TC, LDL-C, HDL-C 
Liu3 [38] 2005 Asian M/F Subjects without CVD and type 2 diabetes TG, TC, LDL-C, HDL-C 
Islam [39] 2005 Caucasian M/F Random subjects TG, TC, LDL-C, HDL-C 
Stancáková [40] 2006 Caucasian M/F Patients with dyslipidemia of metabolic syndrome TC, LDL-C, HDL-C 
Herron [41] 2006 Caucasian M/F Random subjects APOC3, TG, LDL-C, HDL-C 
Huang [42] 2006 Asian M/F Subjects with hypertriglyceridemia or normal APOC3, TG 
Fiegenbaum1 [43] 2007 Caucasian M Random healthy subjects TG, HDL-C 
Fiegenbaum2 [43] 2007 Caucasian F Random healthy subjects TG, HDL-C 
Nieminen [44] 2007 Caucasian M/F Random youth TG, TC, LDL-C, HDL-C 
Parzianello1 [45] 2008 Asian M/F Subjects with hypertriglyceridemia TG, TC, LDL-C, HDL-C 
Parzianello2 [45] 2008 Asian M/F Subjects free of hypertriglyceridemia TG, TC, LDL-C, HDL-C 
Dallongeville [46] 2008 Caucasian M/F Random subjects TG, HDL-C 
Ruiz1 [47] 2008 Caucasian M Random healthy children TG, TC, LDL-C, HDL-C 
Ruiz2 [47] 2008 Caucasian F Random healthy children TG, TC, LDL-C, HDL-C 
Smith1 [48] 2009 Caucasian M/F Patients with type 2 diabetes TG, TC, LDL-C, HDL-C 
Smith2 [48] 2009 Caucasian M/F Subjects free of type 2 diabetes TG, TC, LDL-C, HDL-C 
Yiyang1 [49] 2010 Asian M/F Random subjects TG, TC, LDL-C, HDL-C 
Yiyang2 [49] 2010 Asian M/F Random subjects TG, TC, LDL-C, HDL-C 
Sediri1 [50] 2011 Other M Males with CVD TG, TC, LDL-C, HDL-C 
Sediri2 [50] 2011 Other M Males without CVD TG, TC, LDL-C, HDL-C 
Abd El-Aziz3 [51] 2011 Other M/F Patients with CVD and controls TG, TC, LDL-C, HDL-C 
Bandegi1 [52] 2011 Other M/F Subjects with primary hyperlipidemia TG, TC, LDL-C, HDL-C 
Bandegi2 [52] 2011 Other M/F Normolipidemic subjects TG, TC, LDL-C, HDL-C 
CVD: cardiovascular disease, M: male, F: female, TG: triglyceride, TC: total cholesterol, LDL-C: low-density lipoprotein cholesterol, HDL-
C: high-density lipoprotein cholesterol. 
Summary statistics 
Sixty-seven comparisons were distinguished according to the categories such as age, gender, 
smoking status, and health condition. Of these, 18, 64, 49, 42 and 54 comparisons were 
included for comparing the differences in APOC3, TG, TC, LDL-C and HDL-C, respectively 
(Table 2). Totally, 23846 subjects were enrolled in this meta-analysis, 74% of them (17592 
subjects) have the CC genotype, and 26% of them (6254 subjects) have the GC or GG 
genotype. 6523, 23528, 15891, 15310 and 19527 subjects were included in comparing the 
differences in APOC3, TG, TC, LDL-C and HDL-C, respectively (Additional file 1: Table 
S1). 
  
Table 2 Meta-analysis of the APOC3 rs5128 polymorphism and plasma APOC3 and 
lipids association 
Groups or subgroups Comparisons (n) Q test P value SMD (95% CI) P 
APOC3     
All 18 0.004 0.22(0.12, 0.31) <0.00001 
All in HWE 15 0.007 0.20(0.09, 0.32) 0.001 
Healthy 12 0.001 0.22(0.08, 0.35) 0.001 
Male 5 0.135 0.11(−0.05, 0.27) 0.170 
Caucasian 11 <0.00001 0.26(0.11, 0.40) 0.001 
Asian 6 0.981 0.15(0.02, 0.29) 0.029 
TG     
All 64 <0.00001 0.33(0.23, 0.44) <0.00001 
All in HWE 48 <0.00001 0.31(0.20, 0.42) <0.00001 
Male 19 0.411 0.14(0.07, 0.21) <0.00001 
Female 8 0.062 0.17(0.04, 0.29) 0.011 
Children 5 <0.00001 0.53(−0.37, 1.44) 0.249 
Caucasian 38 <0.00001 0.39(0.24, 0.54) <0.00001 
Asian 17 0.302 0.18(0.12, 0.25) < 0.00001 
Other 9 < 0.00001 0.37(0.04, 0.69) 0.026 
Healthy 39 < 0.00001 0.24(0.13, 0.35) < 0.00001 
CVD 9 0.188 0.29(0.16, 0.43) < 0.00001 
TC     
All 49 < 0.00001 0.15(0.09, 0.22) < 0.00001 
All in HWE 41 0.06 0.12(0.07, 0.18) < 0.00001 
Male 13 0.52 0.06(−0.01, 0.14) 0.105 
Female 6 0.23 0.20(0.07, 0.33) 0.002 
Children 4 0.062 0.30(0.05, 0.55) 0.021 
Caucasian 26 0.08 0.11(0.05, 0.18) 0.001 
Asian 14 0.19 0.15(0.06, 0.24) 0.001 
Other 9 < 0.00001 0.25(−0.03, 0.53) 0.081 
Healthy 39 0.53 0.10(0.06, 0.14) < 0.00001 
CVD 7 0.46 0.15(0.04, 0.26) 0.008 
Type 2 diabetes 4 0.18 0.24(0.05, 0.43) 0.013 
LDL-C     
All 42 < 0.00001 0.11(0.04, 0.17) 0.001 
All in HWE 34 0.043 0.07(0.01, 0.13) 0.021 
Male 11 0.069 0.06(−0.10, 0.12) 0.847 
Female 6 0.197 0.13(0.02, 0.24) 0.021 
Children 4 0.109 0.28(0.05, 0.51) 0.016 
Caucasian 21 0.134 0.06(0.00, 0.13) 0.051 
Asian 13 0.262 0.09(0.01, 0.16) 0.021 
Other 8 < 0.00001 0.22(−0.06, 0.50) 0.119 
Healthy 28 0.159 0.06(0.01, 0.11) 0.012 
CVD 4 0.115 0.07(−0.13, 0.27) 0.482 
Type 2 diabetes 4 0.996 0.22(0.08, 0.36) 0.002 
HDL-C     
All 54 0.314 −0.03(−0.06, 0.01) 0.156 
All in HWE 42 0.195 −0.01(−0.06, 0.03) 0.597 
Male 16 0.474 −0.01(−0.13, 0.00) 0.062 
Female 7 0.663 −0.03(−0.11, 0.06) 0.540 
Children 4 0.989 0.03(−0.13, 0.19) 0.733 
Caucasian 30 0.763 −0.06(−0.10, −0.02) 0.007 
Asian 16 0.173 0.06(−0.02, 0.13) 0.156 
Other 8 0.562 −0.03(−0.06, 0.01) 0.536 
Healthy 35 0.332 −0.03(−0.07, 0.011) 0.160 
CVD 8 0.632 −0.02(−0.13, 0.09) 0.729 
Type 2 diabetes 4 0.656 0.01(−0.14, 0.15) 0.915 
CVD: cardiovascular disease, TG: triglyceride, TC: total cholesterol, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density 
lipoprotein cholesterol. 
Associations of the APOC3 rs5128 polymorphism with APOC3 and lipid levels 
The outcomes of the analyses on all comparisons showed that the G carriers had higher levels 
of APOC3 (SMD: 0.22, 95% CI: 0.12-0.31, P < 0.00001), TG (SMD: 0.33, 95% CI: 0.23-
0.44, P < 0.00001), TC (SMD: 0.15, 95% CI: 0.09-0.22, P < 0.00001), and LDL-C (SMD: 
0.11, 95% CI: 0.04-0.17, P = 0.001) than the non-carriers (Table 2, Figures 1, 2, 3, 4). No 
statistically significant difference in the levels of HDL-C (SMD: −0.03, 95% CI: −0.06-0.01, 
P = 0.156) was detected between the G carriers and the non-carriers (Table 2, Figure 5). In 
the available studies in HWE, the associations between the APOC3 rs5128 polymorphism 
and higher levels of APOC3 (SMD: 0.20, 95% CI: 0.09-0.32, P = 0.001), TG (SMD: 0.31, 
95% CI: 0.20-0.42, P < 0.00001), TC (SMD: 0.12, 95% CI: 0.07-0.18, P < 0.00001) and 
LDL-C (SMD: 0.07, 95% CI: 0.01-0.13, P = 0.021) were also significant (Table 2). 
Figure 1 Forest plot of the APOC3 rs5128 polymorphism and the plasma levels of APOC3 
association. Result from the analysis on all 18 comparisons. 
Figure 2 Forest plot of the APOC3 rs5128 polymorphism and plasma levels of triglycerides 
association. Result from the analysis on all 64 comparisons. 
Figure 3 Forest plot of the APOC3 rs5128 polymorphism and the plasma levels of total 
cholesterol association. Result from the analysis on all 49 comparisons. 
Figure 4 Forest plot of the APOC3 rs5128 polymorphism and plasma levels of LDL-C 
association. Result from the analysis on all 42 comparisons. 
Figure 5 Forest plot of the APOC3 rs5128 polymorphism and plasma levels of HDL-C 
association. Result from the analysis on all 54 comparisons. 
Then the subgroup analyses stratified by the characteristics of the subjects were performed. 
The associations between the APOC3 rs5128 polymorphism and higher levels of APOC3 and 
TG were found to be significant across all subpopulations except that in male subjects for 
APOC3 (SMD: 0.11, 95% CI: −0.05-0.27, P = 0.170) and children for TG (SMD: 0.53, 95% 
CI: −0.37-1.44, P = 0.249) (Table 2). The associations between the APOC3 rs5128 
polymorphism and higher TC levels were significant across all subpopulations except that in 
males (SMD: 0.06, 95% CI: −0.01-0.14, P = 0.105) and other ethnic origins (SMD: 0.25, 
95% CI: −0.03-0.53, P = 0.081). The significant associations between the APOC3 rs5128 
polymorphism and higher LDL-C levels were detected in females (SMD: 0.13, 95% CI: 0.02-
0.24, P = 0.021), children (SMD: 0.28, 95% CI: 0.05-0.51, P = 0.016), Asians (SMD: 0.09, 
95% CI: 0.01-0.16, P = 0.021), and marginally in Caucasians (SMD: 0.06, 95% CI: 0.00-
0.13, P = 0.051). The associations between the APOC3 rs5128 polymorphism and higher 
levels of LDL-C were also significant in healthy subjects (SMD: 0.06, 95% CI: 0.01-0.11, P 
= 0.012) and diabetic patients (SMD: 0.22, 95% CI: 0.08-0.36, P = 0.002) (Table 2). The 
associations between the APOC3 rs5128 polymorphism and lower levels of HDL-C were not 
significant across all subgroups except that in Caucasians (SMD: −0.06, 95% CI: −0.10--
0.02, P = 0.007). 
Heterogeneity analysis and publication bias 
There was significant heterogeneity among the total comparisons for APOC3, TG, TC, and 
LDL-C. Seven comparisons (shoulders, 1996, Russo1, 2001, Dallongeville1, 2000, 
Aburatani, 1988, Olivieri, 2002, Dallongeville2, 2000, Herron, 2006), 12 comparisons 
(shoulders, 1996, Smith1, 2009, Smith2, 2009, Abd El-Aziz3, 2011, Parzianello2, 2008, 
Sediri1, 2011, Dallongeville, 2008, Waterworth1, 2000, Bandegi1, 2011, Espino-Montoro, 
2003, Chhabra1, 2004, Waterworth3, 2000), 3 comparisons (Abd El-Aziz3, 2011, Russo1, 
2001, Liu1, 2005) and 4 comparisons (Nieminen, 2007, Abd El-Aziz3, 2011, de França1, 
2005, Liu1, 2005) were respectively identified as the main contributors of the heterogeneity 
for APOC3, TG, TC, and LDL-C by using Galbraith plot. The heterogeneity was effectively 
removed or decreased after exclusion of these outlier studies, but the SMD values and their 
95% CI did not change significantly (APOC3: SMD: 0.14, 95% CI: 0.03-0.26, P = 0.018, 
Pheterogeneity = 0.158; TG: SMD: 0.17, 95% CI: 0.14-0.21, P < 0.00001, Pheterogeneity = 0.311; 
TC: SMD: 0.12, 95% CI: 0.08-0.17, P < 0.00001, Pheterogeneity = 0.152; LDL-C: SMD: 0.07, 
95% CI: 0.03-0.12, P = 0.002, Pheterogeneity = 0.270). No significant heterogeneity was found 
among the total comparisons and the subgroup analyses for HDL-C. 
The Egger’s test revealed that no publication bias was present in the analyses for APOC3 (t: 
1.94, 95% CI: −0.14-3.13, P = 0.071), TG (t: 1.57, 95% CI: −0.37-3.09, P = 0.121), TC (t: 
1.13, 95% CI: −0.44-1.56, P = 0.264), LDL-C (t: 0.85, 95% CI: −0.66-1.61, P = 0.402), and 
HDL-C (t: −0.85, 95% CI: −0.92-0.38, P = 0.402). Figures A-E of the Additional file 2: 
Figure S1 are the Egger’s plots for APOC3, TG, TC, LDL-C and HDL-C, respectively. 
Discussion 
A genome-wide association study has suggested that the polymorphisms in or near the 
APOC3 gene are among the strongest genetic determinants of plasma lipid concentrations 
[55]. A large body of literature has investigated the associations of the APOC3 rs5128 
polymorphism with plasma APOC3 and/or lipid levels [11-52]. Associations of this 
polymorphism with increased levels of APOC3 [14,20,27,41,42], TG 
[18,20,23,25,28,30,32,33,38,41,42,44,46,51], TC [18,32,51] and LDL-C [30,51], and/or 
decreased levels of HDL-C [24] have been reported in some, but not all studies. The lack of 
consistency across these studies reflects some existed limitations such as small sample size, 
ethnic differences and research methodology. In the present meta-analysis, the associations of 
the APOC3 rs5128 polymorphism with plasma APOC3 and lipid levels were investigated to 
examine these discrepancies. 
The frequencies of the GG homozygote were very low across the populations. Most of the 
included studies only provided data for CC genotype and G allele carriers (GC + GG), and 
did not provide data separately for heterozygote CG and homozygote GG. Therefore, a 
dominant model (CC vs. CG + GG) was employed for this meta-analysis to ensure adequate 
statistical power. The results suggested that the APOC3 rs5128 polymorphism was 
significantly associated with fasting plasma levels of APOC3, TG, TC, and LDL-C under the 
dominant model. The carriers of G allele had higher levels of APOC3, TG, TC, and LDL-C 
than the non-carriers. A recent meta-analysis [10] demonstrated that the rs5128 
polymorphism is associated with CVD risk. CVD is recognized as a multifactorial disease, 
and dyslipidemia accounts for at least 50% of the population-attributable risk [2]. Taken our 
results together, it is possible that the association between the rs5128 polymorphism and 
CVD is mediated by the dyslipidemia caused by the G allele of the rs5128 polymorphism. 
Subgroup analyses by age, gender, ethnicity and health condition were performed since they 
might be important variables in determining associative risk with dyslipidemia. For example, 
the present analyses indicated that age might modulate the association between the rs5128 
polymorphism and TG levels since the significant association especially exists in males and 
females, but not in children (Table 2). In addition, the significant effects of the rs5128 
polymorphism on TC and LDL-C exist in females and children, but not in males; the 
significant effect of the polymorphism on LDL-C exists in healthy subjects and diabetic 
patients, but not in CVD patients. More studies should be conducted to further examine the 
association of this polymorphism with LDL-C in CVD patients. The associations of the 
rs5128 polymorphism with plasma levels of APOC3, TG, TC and LDL-C were very robust, 
which did not vary greatly when the analyses were performed only with the available studies 
in HWE. However, the significant association of the APOC3 rs5128 polymorphism with 
plasma HDL-C levels was not detected in this meta-analysis. 
Significant heterogeneity was found across the analyses for APOC3, TG, TC, and LDL-C. 
The main sources of heterogeneity were from ethnic origin, study design, gender and health 
condition of the subjects, etc. Subgroup analyses stratified by the characteristics of the 
subjects were performed to explore the potential source of the observed heterogeneity, and 
significant heterogeneity was still observed in some subgroups. Galbraith plot was employed 
to further evaluate the sources of heterogeneity. Outlier studies were identified by using the 
plot, and the heterogeneity was effectively removed or decreased after exclusion of these 
outlier studies. No significant changes of the SMD value were found after excluding the 
outlier studies. 
The associations of the APOC3 rs5128 polymorphism with plasma APOC3, TG, TC and 
LDL-C were not likely to be type I errors (false-positive results). Firstly, the results from this 
meta-analysis were based on the random effects model. Comparing with fixed effects model, 
the random effects model is a more conservative method and less likely to produce false-
positive results. Secondly, 42 studies with 23846 subjects were included in this meta-
analysis. Among the subjects, 26% of them were the carriers of the rs5128 G allele. Since the 
incidence of the G allele carriers was sufficiently high, type I error may have been prevented. 
The possible mechanism under which the rs5128 polymorphism modulates plasma APOC3 
has not been clarified yet. One explanation could be that the G allele enhances the 
transcriptional activity of APOC3 and leads to a higher plasma APOC3 level since the rs5128 
polymorphism is located in the 3'UTR of exon 4 of this gene. In the present analyses, a 
significant higher level of APOC3 was found in G carriers comparing with the CC genotype 
subjects. Previous studies have shown that APOC3 can increase plasma TG levels. Three 
mechanisms are involved in the elevation of TG levels by APOC3. Firstly, APOC3 promotes 
the assembly and secretion of VLDL in liver [56-58]. Overexpression of APOC3 in McA-
RH7777 cells by recombinant adenovirus expression vector resulted in significantly increased 
VLDL assembly and secretion with a dose-dependent effect [56]. APOC3 gene knockout 
mice showed no increase in VLDL secretion after two weeks of high-fat diet [57]. Functional 
analysis found that two regions on the APOC3 polypeptide chain are closely related to VLDL 
synthesis and secretion [57,58]. Secondly, APOC3 inhibits LPL, which is located on the inner 
side of capillaries and is the main enzyme to hydrolyze TG-rich particles [59]. Thirdly, 
APOC3 inhibits hepatic lipase. Hepatic lipase is located on the endothelial side of liver 
sinusoids, and its main function is to remove the remnants of chylomicron and VLDL. 
The present meta-analysis also suggested the significant associations of the rs5128 
polymorphism with higher levels of LDL-C and TC. There is interrelationship between TG 
metabolism and cholesterol metabolism in the body, so the elevation of VLDL-TG by 
APOC3 might have disturbed the cholesterol metabolism and increased plasma LDL-C and 
TC levels. For example, LDL particles are formed in the bloodstream as VLDL particles lose 
TG through the action of LPL. Hence, the increase of VLDL Levels can cause the elevation 
of LDL levels, and accordingly the LDL-C levels. Since approximately 70% of plasma 
cholesterol molecules are resided in LDL particles, the elevation of LDL-C can lead to higher 
levels of TC. In addition, it is likely that the rs5128 polymorphism is in linkage 
disequilibrium with other causative mutations involved in the metabolism of LDL. APOC3 is 
a member of the APOA1/C3/A4/A5 gene cluster which is the key component in modulating 
lipid metabolism [60]. Several polymorphism sites in the APOA1/C3/A4/A5 gene cluster 
have been found to significantly affect plasma LDL-C levels [61]. 
In the current study, we did not find significant association between the APOC3 rs5128 
polymorphism and lower levels of HDL-C by meta-analysis. One reason could be that HDL 
is metabolized independently of APOC3 [4,5]. Unlike VLDL and LDL, nascent HDL 
particles are mainly formed in liver, matured in bloodstream and go back to liver with full 
load of cholesteryl ester molecules. In this process, HDL is mainly regulated by the proteins 
such as apolipoprotein A1 (APOA1), ATP-Binding cassette transporter A1 (ABCA1) and 
cholesteryl ester transfer protein (CETP) [62]. Therefore, the APOC3 rs5128 polymorphism 
was found to be associated with the plasma levels of APOC3, TG, LDL-C and TC, but not 
HDL-C. 
The limitations of the present meta-analysis should be noted. Firstly, dyslipidemia is involved 
in a number of genes as well as some environmental factors. However, the interactions of the 
rs5128 polymorphism with other polymorphic loci or environmental factors on plasma 
APOC3 and lipid levels have not been investigated in this analysis due to the lack of the 
original data of the included studies. In other words, the more precise results could have been 
gained if more detailed individual data were available or the stratification analyses based on 
the environmental factors such as diet, exercise, and smoking status were performed. 
Secondly, a relatively small number of subjects were included for the association analysis 
between the rs5128 polymorphism and plasma APOC3 levels due to the limited available 
studies, which may reduce the statistic power and even cause the type II errors (false-negative 
results). More studies with larger sample size are required to further investigate the 
association. Thirdly, this meta-analysis only included the studies published in English 
because it was very difficult to get the full papers published in various languages. 
Conclusions 
In conclusion, the significant associations between the APOC3 rs5128 polymorphism and 
higher levels of APOC3, TG, TC, and LDL-C were found in the present meta-analysis. 
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